Latest News and Press Releases
Want to stay updated on the latest news?
-
– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviralagents progresses – ...
-
– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication – – Cocrystal is currently further conducting preclinical studies of these coronavirus...
-
- Company has sufficient capital to advance pipeline and fund operations through 2021 - BOTHELL, WA, May 14, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the...
-
- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program - - Small molecule therapeutic inhibitors against coronaviruses included in agreement have...
-
Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
-
Company has immediately initiated Coronavirus programLeveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial position bolsters Company’s...